Saturday 17 October 2026 Export XGN’s income statement to Excel — free account

Exagen Inc.

Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 15.9%, EPS grew 38.1%, free cash flow grew 211.3% and total debt rose 6.44%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.65 0.91 −10.63%

Follow XGN

Alert me

Market cap: $207.4M
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 3/9
Altman Z: −4.58
Beneish M: −2.80
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.25

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	2	1	—	—	—	—	—	1	—

Insider Ownership 39.62%

Capital & Financial Ratios $m

Market Cap 207.37

Revenue 71.12

Net Income (18.92)

Free Cash Flow (7.58)

Net Debt (0.13)

Current Ratio 3.18

Debt/Equity 2.00

P/E ratio 0.00

Fwd P/E (6.22)

P/S ratio 2.60

P/B ratio 15.13

Past 5Y EPS Growth —

This Y EPS Growth 29.71%

Next Y EPS Growth 23.57%

Next Y revenue growth 11.02%

Next 5Y EPS Growth 29.44%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 64.05%

10-year low 10-year high

P/B against its own 10 years 95.99%

10-year low 10-year high

EV/Sales against its own 10 years 72.84%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	36	22	32	25
Receivables	7	8	11	12
Inventory	—	—	—	—
Other	—	—	—	—
	48	36	49	43

	2023	2024	2025	Q'26
Payables	3	4	4	4
ST’ Debt	0	0	1	1
Other	—	—	—	—
	12	14	14	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	9.66%	13.47%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(16.05%)	(25.65%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	17	20	—	—	—
’25	15	17	17	17	67
’24	14	15	13	14	56
’23	11	14	13	14	53
’22	10	8	15	13	46
’21	11	13	12	13	48
’20	10	9	11	13	42

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	4	—	—	—
’25	(11)	(3)	3	(3)	(14)
’24	(9)	(2)	(2)	0	(13)
’23	(10)	(10)	(3)	8	(14)
’22	(9)	(11)	(7)	(6)	(32)
’21	(4)	(4)	(5)	(6)	(20)
’20	(3)	(5)	(2)	(4)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	3	—	—	—
’25	(11)	(3)	3	(3)	(14)
’24	(9)	(3)	(2)	0	(14)
’23	(10)	(10)	(3)	8	(15)
’22	(10)	(13)	(8)	(6)	(36)
’21	(4)	(5)	(6)	(7)	(23)
’20	(3)	(5)	(2)	(4)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.13)	—	—	—
’25	(0.20)	(0.21)	(0.31)	(0.20)	(0.93)
’24	(0.19)	(0.16)	(0.28)	(0.20)	(0.83)
’23	(0.44)	(0.28)	(0.31)	(0.31)	(1.34)
’22	(0.60)	(0.78)	(0.47)	(0.83)	(2.77)
’21	(0.48)	(0.38)	(0.42)	(0.42)	(1.68)
’20	(0.44)	(0.27)	(0.34)	(0.27)	(1.32)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	11.54	10.29	8.60	2.10	1.33	1.30	2.67	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	29.86	26.99	24.67	11.68	3.92	6.22	12.23
People
People	Employees	—	—	144	156	183	222	204	179	209	220
	Revenue/emp, $m	—	0.00	0.23	0.26	0.23	0.22	0.22	0.29	0.27	0.30
Income, $m
Income, $m	Revenue	—	27	32	40	42	48	46	53	56	67
	Gross margin, %	—	46.57	52.59	53.43	60.55	57.37	46.86	56.06	59.51	58.28
	EBT	—	(26)	(8)	(12)	(17)	(27)	(48)	(24)	(15)	(20)
	EBT margin, %	—	(97.66)	(24.52)	(29.74)	(39.94)	(55.23)	(104.62)	(45.02)	(27.14)	(29.89)
	Net income	—	0	(8)	(12)	(17)	(27)	(47)	(24)	(15)	(20)
	Depreciation	—	1	1	1	1	1	7	2	2	3
Per share, $
Per share, $	Revenue	—	2.23	514.92	11.28	3.32	3.02	2.67	2.97	3.06	3.09
	Earnings	—	(2.72)	(127.17)	(8.46)	(1.32)	(1.68)	(2.77)	(1.34)	(0.83)	(0.93)
	Cash flow	—	(0.91)	(147.63)	(2.71)	(1.11)	(1.27)	(1.88)	(0.82)	(0.73)	(0.63)
	Capex	—	0.00	(3.16)	(0.03)	(0.04)	(0.15)	(0.25)	(0.05)	(0.03)	(0.03)
	Free cash flow	—	(0.91)	(150.79)	(2.74)	(1.15)	(1.42)	(2.13)	(0.86)	(0.76)	(0.66)
	Book value	—	(0.39)	(106.89)	15.55	3.31	5.32	2.49	1.28	0.52	0.81
	Shares, m	—	12	0	4	13	16	17	18	18	22
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	0.00	2.25	3.97	3.85	0.92	0.66	1.34	1.97
	P/B	—	0.00	0.00	1.63	3.99	2.19	0.99	1.53	7.82	7.51
	EV/Sales	—	0.00	0.00	1.11	3.25	2.37	0.19	0.34	1.31	1.86
	EV/FCF	—	(0.92)	(0.92)	(4.58)	(9.37)	(5.05)	(0.24)	(1.17)	(5.29)	(8.68)
Cash, $m
Cash, $m	Operating cash flow	—	(11)	(9)	(10)	(14)	(20)	(32)	(14)	(13)	(14)
	Capex	—	(1)	0	0	0	(2)	(4)	(1)	(1)	(1)
	Free cash flow	—	(11)	(9)	(10)	(15)	(23)	(36)	(15)	(14)	(14)
Balance, $m
Balance, $m	Working capital	—	8	12	75	62	103	63	36	23	35
	Total debt	—	20	28	26	27	28	29	19	20	25
	Net debt	—	8	15	(46)	(30)	(71)	(33)	(17)	(2)	(7)
	Shareholders’ equity	—	(5)	(7)	56	42	85	42	23	10	17
Returns, %
Returns, %	ROA	—	(448.13)	(84.95)	(51.67)	(20.02)	(26.61)	(45.20)	(33.09)	(29.74)	(38.85)
	ROIC	—	0.00	(35.67)	(60.12)	(83.56)	(110.94)	(318.49)	(250.58)	(107.80)	(87.10)
	ROE	—	41.96	17.72	107.55	(34.23)	(42.36)	(74.39)	(72.72)	(93.78)	(147.85)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
FLGT Fulgent Genetics, Inc.	$587.2M	— (loss-making)	— (loss-making)	+4.38% (above 0%: growing)	n/m	+25.36% (above 0%: growing)	30.07%	(42.25%)	Compare
MYGN Myriad Genetics, Inc.	$416.1M	— (loss-making)	— (loss-making)	−10.51% (below 0%: shrinking)	n/m	+43.90% (above 0%: growing)	66.60%	(20.40%)	Compare
BDSX Biodesix, Inc.	$260.7M	— (loss-making)	— (loss-making)	+34.18% (above 0%: growing)	n/m	+72.75% (above 0%: growing)	82.06%	(20.06%)	Compare
XGN Exagen Inc.	$207.4M	— (loss-making)	— (loss-making)	+15.92% (above 0%: growing)	n/m	+211.34% (above 0%: growing)	61.27%	(8.64%)
BNR Burning Rock Biotech Limited Sponsored ADR	$137.1M	— (loss-making)	11.1×	−4.22% (below 0%: shrinking)	n/m	+46.01% (above 0%: growing)	72.58%	(13.36%)	Compare
MDXHF MedX Health Corp.	$103.2M	— (loss-making)	— (loss-making)	+33.59% (above 0%: growing)	n/m	+41.60% (above 0%: growing)	37.19%	(1,027.95%)	Compare
IMDX Insight Molecular Diagnostics Inc.	$100.1M	— (loss-making)	— (loss-making)	−53.86% (below 0%: shrinking)	n/m	−54.02% (below 0%: shrinking)	65.69%	(4,770.71%)	Compare
QUCY Quantum Cyber N.V	$95.1M	— (loss-making)	— (loss-making)	+11.12% (above 0%: growing)	n/m	+26.73% (above 0%: growing)	62.71%	0.00%	Compare
MDXH MDxHealth SA	$57.6M	— (loss-making)	— (loss-making)	+12.01% (above 0%: growing)	n/m	−200.20% (below 0%: shrinking)	65.75%	(18.74%)	Compare
Median of peers	$120.1M	—	—	+7.75%	—	+34.17%	65.72%	(20.23%)

All 52 Diagnostics & Research stocks →

Exagen Inc. (XGN) key facts

Strength: Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024.
Exagen Inc. (XGN) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, XGN traded at $7.65, a market capitalization of $207.4 million.
Return on equity was −147.9% and debt-to-equity 2.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.58 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.